相关临床试验
13
4 进行中
药物批准
21
批准总数
监管机构
1
监管机构数
成立时间
1954
进行中（未招募）
2
15.4%
Approved For Marketing
1
7.7%
已完成
6
46.1%
尚未招募
2
15.4%
终止
1
7.7%
撤回
1
7.7%
- Cellectis' board approved a strategic transformation on September 11, 2026, ending internal development of CAR-T candidates lasme-cel and eti-cel and refocusing on in vivo gene editing. - The company will advance two preclinical programs, .HEAL-101 targeting APOC3 for severe hypertriglyceridemia and .HEAL-201 targeting PCSK9 for severe hypercholesterolemia, both LNP-delivered. - Cellectis attributed the CAR-T exit to improved frontline regimens, bispecific antibody competition and slower enrollment, and will seek partners for the discontinued assets. - The operational realignment is designed to extend the cash runway into H2 2028, with preliminary Phase 1 data from .HEAL-101 expected in H2 2027 and .HEAL-201 in H1 2028.
- Owkin will license its K Pro AI Scientist platform and multimodal patient data to Servier to support oncology research into hard-to-treat cancers. - Servier researchers gain access to patient-level data from Owkin's MOSAIC network for analysis within the K Pro platform. - The deal expands a prior Owkin-Servier collaboration focused on patient subgroup identification in oncology into a broader AI-powered research environment. - K Pro supports molecule optimization, target discovery, biomarker identification, subgroup optimization and clinical trial design across drug development.
- Insilico Medicine dosed the first patient with Rentosertib in the Phase III GENESIS-IPF-3 trial for idiopathic pulmonary fibrosis at Peking Union Medical College Hospital. - The 52-week randomized, double-blind, placebo-controlled study will enroll 320 patients across 47 centers in China, with FVC decline as the primary endpoint. - Rentosertib is a potentially first-in-class small molecule targeting TNIK, a fibrosis pathway identified through AI-driven discovery and never previously linked to fibrosis. - Insilico reported first-half 2026 revenue of about $106 million, a 287% year-over-year increase, and its first profitable half-year since listing.
- IDEAYA Biosciences and Servier have dosed the first patient in OptimUM-11, a global Phase III registrational trial of darovasertib plus crizotinib as adjuvant therapy in primary uveal melanoma. - The trial will enroll approximately 450 patients at elevated risk of metastatic recurrence after local therapy, randomizing them 1:1 to 12 months of the combination or observation. - Relapse-free survival is the primary endpoint in a setting where no adjuvant treatment is currently approved, despite up to 50% of patients developing metastatic disease. - The companies are simultaneously running three randomized Phase III registrational trials of darovasertib across metastatic, neoadjuvant and adjuvant uveal melanoma.
- Nitza Thomasson joined Servier in March 2025 as Executive Director and Global Head of R&D Neurology to build the company's rare neurology therapeutic area from scratch. - Servier currently has three neurology drugs in its pipeline, targeting rare refractory epilepsies, movement disorders, neuromuscular disorders, and other conditions. - The company recently strengthened its portfolio through the acquisition of Edgewise Therapeutics' neuromuscular dystrophy pipeline. - Thomasson emphasizes that success in rare neurology requires embracing scientific uncertainty, adapting approaches to each disease, and building a team culture grounded in trust and high expectations.
- Vorasidenib (Voranigo) becomes the first targeted treatment for IDH-mutant astrocytoma and oligodendroglioma listed on Australia's Pharmaceutical Benefits Scheme in over two decades. - The PBS listing reduces the cost from $28,000 per month to a maximum of $25 per script, benefiting approximately 135 Australians diagnosed annually. - The oral therapy targets mutations in IDH1 or IDH2 genes, blocking mutated proteins that drive cancer growth and potentially slowing disease progression. - Patients are typically diagnosed between ages 20 and 45, with the disease causing seizures, cognitive decline, physical disability, and loss of independence.
- Servier has enrolled the first patient in a first-in-human Phase Ib/II study evaluating an antisense oligonucleotide (ASO) targeting KCNT1-related developmental and epileptic encephalopathy (KCNT1-DEE) in children. - The investigational ASO is designed to degrade KCNT1 mRNA, addressing the genetic root cause of this devastating early-onset epilepsy syndrome that currently has no curative or disease-modifying treatments. - Global clinical trial sites are now open and actively enrolling patients across the U.S., Europe, and Japan, with the asset developed internally by Servier scientists. - This milestone reinforces Servier's strategic commitment to rare neurological disorders, complementing a separate multi-target ASO research collaboration with the n-Lorem Foundation announced earlier in June 2026.
- Servier will present updated long-term efficacy and safety data from the Phase 3 INDIGO trial of VORANIGO (vorasidenib) for IDH-mutant glioma, with over three years of follow-up supporting sustained treatment benefits. - Day One Biopharmaceuticals will share promising Phase 1 results for Emi-Le, a B7-H4-directed ADC showing favorable tolerability and antitumor activity in aggressive adenoid cystic carcinoma patients. - The presentations at ASCO 2026 demonstrate Servier's expanding rare oncology portfolio, targeting high unmet medical needs in brain tumors and rare cancers.
- The FDA has granted breakthrough therapy designation to emiltatug ledadotin (Emi-Le), a B7-H4-directed antibody-drug conjugate, for treating locally advanced, recurrent or metastatic adenoid cystic carcinoma with solid histology or high-grade transformation. - Phase 1 trial data demonstrated a manageable safety profile with 83.0% any-grade treatment-related adverse events and achieved a 55.6% overall response rate in evaluable patients with ACC type 1. - Adenoid cystic carcinoma affects more than 200,000 people globally with no currently approved systemic therapies for advanced or metastatic disease, representing a significant unmet medical need.
- General Proximity, a San Francisco biotech company, received investment from FreeMind Investments and Daewoong Pharmaceutical for its innovative induced proximity medicine platform. - The company's proprietary OmniTAC platform scans the "effectome" to identify effector proteins that can modulate previously undruggable disease-causing targets. - General Proximity has secured over $20 million in funding, five "Golden Ticket" awards from major pharma companies, and a strategic collaboration with Daiichi Sankyo. - The investment reflects Daewoong Pharmaceutical's strategic interest in exploring future collaboration opportunities with General Proximity's platform technology.
